SELLAS Life Sciences Group, Inc. (SLS)
NASDAQ
Closed
Oct 9, 2026
Day's Range
11.2652 wk Range
1.39Overview - SLS - SELLAS Life Sciences Group, Inc.
Key Statistics
Valuation
Enterprise Value
2.28B
P/E (Trailing)
‪-46.47‬
P/E (Forward)
‪-119.79‬
PEG Ratio
‪1.62‬
Price / Book
‪17.56‬
EV / EBITDA
‪-80.77‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Return on Assets
‪-23.29%‬
Return on Equity
‪-39.63%‬
Ownership
Shares Outstanding
201.91M
Float
201.14M
Short % of Shares Outstanding
‪28.80%‬
Held by Insiders
‪0.92%‬
Held by Institutions
‪37.00%‬
Price stats
Beta
‪2.52‬
50-Day Avg
‪12.42‬
200-Day Avg
‪7.44‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
2 analysts
Average price target
‪$ 32.50‬Shariah Compliance
Report Date: Feb 19, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - SLS - SELLAS Life Sciences Group, Inc.
Peers - SLS - SELLAS Life Sciences Group, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- SLSNASDAQSELLAS Life Sciences Group, Inc.2.34BMarket Cap+86.56%52-week change-46.48P/E (Trailing)‪0.00%‬Profit Margin
- ARGXNASDAQArgenx SE57.50BMarket Cap+14.28%52-week change34.96P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.29.40BMarket Cap-105.72%52-week change38.35P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share24.34BMarket Cap-8.52%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S14.99BMarket Cap+7.48%52-week change17.72P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.13.14BMarket Cap+18.80%52-week change-17.80P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.11.06BMarket Cap+2.75%52-week change154.54P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - SLS - SELLAS Life Sciences Group, Inc.
About
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on developing novel therapies for cancer. SELLAS Life Sciences Group, Inc. concentrates on immunotherapeutic and targeted oncology programs designed to address a broad range of hematologic and solid tumor indications. Its…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
